Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems

Antiviral Research

Volumn 136, Issue , 2016, Pages 9-18

  Welch, Stephen R ^a   Guerrero, Lisa Wiggleton ^a   Chakrabarti, Ayan K ^a   McMullan, Laura K ^a   Flint, Mike ^a   Bluemling, Gregory R ^b   Painter, George R ^b   Nichol, Stuart T ^a   Spiropoulou, Christina F ^a   Albariño, César G ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZAURIDINE; LAMIVUDINE; LUCIFERASE; RIBAVIRIN; STAVUDINE; TENOFOVIR; ZIDOVUDINE; 2'-FLUORO-2'-DEOXYCYTIDINE; ANTIVIRUS AGENT; DEOXYCYTIDINE; GREEN FLUORESCENT PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; LASSA FEVER; LASSA VIRUS; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; UNTRANSLATED REGION; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS RECOMBINANT; VIRUS TITRATION; WILD TYPE; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; PROCEDURES;

ANTIVIRAL AGENTS; AZAURIDINE; DEOXYCYTIDINE; DRUG DISCOVERY; EBOLAVIRUS; GENES, REPORTER; GENOME, VIRAL; GREEN FLUORESCENT PROTEINS; HEMORRHAGIC FEVER, EBOLA; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LASSA FEVER; LASSA VIRUS; LUCIFERASES;

EID: 84992735522     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.10.007     Document Type: Article

References (33)

1. Albariño, C.G., Guerrero, L.W., Chakrabarti, A.K., Kainulainen, M.H., Whitmer, S.L., Welch, S.R., Nichol, S.T., Virus fitness differences observed between two naturally occurring isolates of Ebola virus Makona variant using a reverse genetics approach. Virology 496 (2016), 237–243.
2. Albariño, C.G., Wiggleton Guerrero, L., Lo, M.K., Nichol, S.T., Towner, J.S., Development of a reverse genetics system to generate a recombinant Ebola virus Makona expressing a green fluorescent protein. Virology 484 (2015), 259–264.
3. Anantpadma, M., Kouznetsova, J., Wang, H., Huang, R., Kolokoltsov, A., Guha, R., Lindstrom, A.R., Shtanko, O., Simeonov, A., Maloney, D.J., Maury, W., LaCount, D.J., Jadhav, A., Davey, R.A., Large scale screening and identification of novel Ebolavirus and Marburgvirus entry inhibitors. Antimicrob. Agents Chemother. 60 (2016), 4471–4481.
4. Boehmann, Y., Enterlein, S., Randolf, A., Muhlberger, E., A reconstituted replication and transcription system for Ebola virus Reston and comparison with Ebola virus Zaire. Virology 332 (2005), 406–417.
5. Chen, J.J., Jones, M.E., Effect of 6-azauridine on de novo pyrimidine biosynthesis in cultured Ehrlich ascites cells. Orotate inhibition of dihydroorotase and dihydroorotate dehydrogenase. J. Biol. Chem. 254 (1979), 4908–4914.
6. Cihlar, T., Ray, A.S., Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antivir. Res. 85 (2010), 39–58.
7. Emonet, S.F., Garidou, L., McGavern, D.B., de la Torre, J.C., Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 3473–3478.
8. Flint, M., McMullan, L.K., Dodd, K.A., Bird, B.H., Khristova, M.L., Nichol, S.T., Spiropoulou, C.F., Inhibitors of the tick-borne, hemorrhagic fever-associated flaviviruses. Antimicrob. Agents Chemother. 58 (2014), 3206–3216.
9. Gane, E.J., Stedman, C.A., Hyland, R.H., Ding, X., Svarovskaia, E., Symonds, W.T., Hindes, R.G., Berrey, M.M., Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368 (2013), 34–44.
10. Geisbert, T.W., Jahrling, P.B., Exotic emerging viral diseases: progress and challenges. Nat. Med. 10 (2004), S110–S121.
11. Goba, A., Khan, S.H., Fonnie, M., Fullah, M., Moigboi, A., Kovoma, A., Sinnah, V., Yoko, N., Rogers, H., Safai, S., Momoh, M., Koroma, V., Kamara, F.K., Konowu, E., Yillah, M., French, I., Mustapha, I., Kanneh, F., Foday, M., McCarthy, H., Kallon, T., Kallon, M., Naiebu, J., Sellu, J., Jalloh, A.A., Gbakie, M., Kanneh, L., Massaly, J.L., Kargbo, D., Kargbo, B., Vandi, M., Gbetuwa, M., Gevao, S.M., Sandi, J.D., Jalloh, S.C., Grant, D.S., Blyden, S.O., Crozier, I., Schieffelin, J.S., McLellan, S.L., Jacob, S.T., Boisen, M.L., Hartnett, J.N., Cross, R.W., Branco, L.M., Andersen, K.G., Yozwiak, N.L., Gire, S.K., Tariyal, R., Park, D.J., Haislip, A.M., Bishop, C.M., Melnik, L.I., Gallaher, W.R., Wimley, W.C., He, J., Shaffer, J.G., Sullivan, B.M., Grillo, S., Oman, S., Garry, C.E., Edwards, D.R., McCormick, S.J., Elliott, D.H., Rouelle, J.A., Kannadka, C.B., Reyna, A.A., Bradley, B.T., Yu, H., Yenni, R.E., Hastie, K.M., Geisbert, J.B., Kulakosky, P.C., Wilson, R.B., Oldstone, M.B., Pitts, K.R., Henderson, L.A., Robinson, J.E., Geisbert, T.W., Saphire, E.O., Happi, C.T., Asogun, D.A., Sabeti, P.C., Garry, R.F., Viral Hemorrhagic Fever, C, An outbreak of Ebola virus disease in the Lassa fever zone. J. Infect. Dis. 214:S3 (2016), S110–S121.
12. Han, Z., Lu, J., Liu, Y., Davis, B., Lee, M.S., Olson, M.A., Ruthel, G., Freedman, B.D., Schnell, M.J., Wrobel, J.E., Reitz, A.B., Harty, R.N., Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses. J. Virol. 88 (2014), 7294–7306.
13. Hass, M., Golnitz, U., Muller, S., Becker-Ziaja, B., Gunther, S., Replicon system for Lassa virus. J. Virol. 78 (2004), 13793–13803.
14. Hensley, L.E., Dyall, J., Olinger, G.G. Jr., Jahrling, P.B., Lack of effect of lamivudine on Ebola virus replication. Emerg. Infect. Dis. 21 (2015), 550–552.
15. Jacobs, M., Aarons, E., Bhagani, S., Buchanan, R., Cropley, I., Hopkins, S., Lester, R., Martin, D., Marshall, N., Mepham, S., Warren, S., Rodger, A., Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers. Lancet Infect. Dis. 15 (2015), 1300–1304.
16. Jasenosky, L.D., Neumann, G., Kawaoka, Y., Minigenome-based reporter system suitable for high-throughput screening of compounds able to inhibit Ebolavirus replication and/or transcription. Antimicrob. Agents Chemother. 54 (2010), 3007–3010.
17. Kim, J.H., Lee, S.R., Li, L.H., Park, H.J., Park, J.H., Lee, K.Y., Kim, M.K., Shin, B.A., Choi, S.Y., High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One, 6, 2011, e18556.
18. Kouznetsova, J., Sun, W., Martinez-Romero, C., Tawa, G., Shinn, P., Chen, C.Z., Schimmer, A., Sanderson, P., McKew, J.C., Zheng, W., Garcia-Sastre, A., Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg. Microbes Infect., 3, 2014, e84.
19. Lo, M.K., Nichol, S.T., Spiropoulou, C.F., Evaluation of luciferase and GFP-expressing Nipah viruses for rapid quantitative antiviral screening. Antivir. Res. 106 (2014), 53–60.
20. Maisa, A., Stroher, U., Klenk, H.D., Garten, W., Strecker, T., Inhibition of Lassa virus glycoprotein cleavage and multicycle replication by site 1 protease-adapted alpha(1)-antitrypsin variants. PLoS Negl. Trop. Dis., 3, 2009, e446.
21. McCarthy, S.D., Majchrzak-Kita, B., Racine, T., Kozlowski, H.N., Baker, D.P., Hoenen, T., Kobinger, G.P., Fish, E.N., Branch, D.R., A rapid screening assay identifies monotherapy with interferon-ss and combination therapies with nucleoside analogs as effective inhibitors of Ebola virus. PLoS Negl. Trop. Dis., 10, 2016, e0004364.
22. McCormick, J., Fisher-Hoch, S., Lassa fever. Curr. Top. Microbiol. Immunol. 262 (2002), 75–109.
23. McCormick, J.B., King, I.J., Webb, P.A., Scribner, C.L., Craven, R.B., Johnson, K.M., Elliott, L.H., Belmont-Williams, R., Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 314 (1986), 20–26.
24. Muhlberger, E., Weik, M., Volchkov, V.E., Klenk, H.D., Becker, S., Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J. Virol. 73 (1999), 2333–2342.
25. Murakami, E., Bao, H., Ramesh, M., McBrayer, T.R., Whitaker, T., Micolochick Steuer, H.M., Schinazi, R.F., Stuyver, L.J., Obikhod, A., Otto, M.J., Furman, P.A., Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob. Agents Chemother. 51 (2007), 503–509.
26. Ngo, N., Cubitt, B., Iwasaki, M., de la Torre, J.C., Identification and mechanism of action of a novel small-molecule inhibitor of arenavirus multiplication. J. Virol. 89 (2015), 10924–10933.
27. Oestereich, L., Rieger, T., Ludtke, A., Ruibal, P., Wurr, S., Pallasch, E., Bockholt, S., Krasemann, S., Munoz-Fontela, C., Gunther, S., Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever. J. Infect. Dis. 213 (2016), 934–938.
28. Reed, L.J., Muench, H., A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27 (1938), 493–497.
29. Stuyver, L.J., McBrayer, T.R., Tharnish, P.M., Clark, J., Hollecker, L., Lostia, S., Nachman, T., Grier, J., Bennett, M.A., Xie, M.Y., Schinazi, R.F., Morrey, J.D., Julander, J.L., Furman, P.A., Otto, M.J., Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir. Chem. Chemother. 17 (2006), 79–87.
30. Uebelhoer, L.S., Albariño, C.G., McMullan, L.K., Chakrabarti, A.K., Vincent, J.P., Nichol, S.T., Towner, J.S., High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses. Antivir. Res. 106 (2014), 86–94.
31. World Health Organisation, Ebola Situation Reports., 2016.
32. Yonezawa, A., Cavrois, M., Greene, W.C., Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha. J. Virol. 79 (2005), 918–926.
33. Zhang, J.H., Chung, T.D., Oldenburg, K.R., A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen 4 (1999), 67–73.